Collusion probe into cancer meds
- Wired World
- 13 Jun 2017 (South Africa)
Johannesburg - The Competition Commission announced it will investigate price fixing of cancer medication.
Commissioner Tembinkosi Bonakele was speaking at a briefing at the Department of Trade and Industry headquarters in Pretoria on Tuesday.
The investigation is to be initiated against oncology medicine provider Roche Products, which includes its US-based biotechnology company Genentech Incorporated.
The commission will also investigate Pfizer, for suspected excessive pricing of lung cancer medication in South Africa. Aspen Pharmacare
The commission plans to obtain evidence from patients.
“We have to treat this with the urgency and sensitivity it deserves, there are still many patients in need of these drugs,” said Bonakele.
"We have to look at patents and how they get abused. A perpetual monopoly aided by patents is unlawful," he said.
This follows a previous report by Fin24 that Aspen is under preliminary investigation for alleged price-fixing.
Aspen is undergoing a legal process with European regulators over allegations that the company secretly planned to destroy life-saving cancer medication European countries to allow price hikes, Fin24 reported.
Reader notice: Our comments service provider, Civil Comments, has stopped operating and will terminate services on 20th Dec 2017. As a result, we will be searching for another platform for our readers. We aim to have this done with the launch of our new site in early 2018 and apologise for the inconvenience.